Clinical Trial Update: Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib [Phase 2]

View source ↗

Summary

Phase 2 trial assessing local ablative treatment optimization in advanced ALK-rearranged non-small cell lung cancer patients treated with brigatinib; currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alunbrig (Brigatinib)

Snippet

Sponsor: Groupe Francais De Pneumo-Cancerologie | Conditions: NSCLC | Phase 2 | Status: RECRUITING